Cisco Systems Inc vs Merck & Co., Inc. — how do they compare? Cisco Systems Inc trades at $116.3 (market cap $452.96B), while Merck & Co., Inc. trades at $142.33 (market cap $351.28B). The key difference: Cisco Systems Inc is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Merck & Co., Inc. for 98 Days on average.
| CSCO | MRK | |
|---|---|---|
Market Cap | $452.96B | $351.28B |
Volume | 12,951,578 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $130.00 | $156.43 |
52-Week Low | $67.46 | $82.49 |
Typical Hold Time | 86 Days | 98 Days |
Enterprise Value | $466.58B | $398.04B |
Dividend Yield | 1.46% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.59% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $1.22 versus $1.17, continuing a trend of earnings outperformance. Technical indicators show a bullish moving average trend while oscillators suggest potential near-term consolidation. Recent news highlights Cisco's AI-driven networking momentum with Splunk integration and partnerships with NVIDIA, supporting multi-year growth prospects in AI infrastructure.
Cisco presents a compelling investment case with robust profitability metrics (64.52% gross margin, 27.32% ROE) and analyst consensus pointing to 13% upside to the $129.77 price target. Key risks include competitive pressure in AI security from Datadog and CrowdStrike, and the stock's elevated valuation multiples (P/E 35.25, P/S 7.39) that require continued execution. The company's strong cash flow generation and dividend payments provide shareholder value support.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →